Cg Oncology Inc

Research Cg Oncology Inc (CGON) on Bullrun: market cap USD 6.49B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCGON
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 6.49B
• Financial periodFY2025
• RevenueUSD 4.04M
• Revenue growth254.7%
• Net income-USD 161.00M
• Free cash flow-USD 132.48M

Valuation Snapshot

latest market cap is USD 6.49B.

About Cg Oncology Inc

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure;

Frequently asked questions

What is Cg Oncology Inc's market cap?

Cg Oncology Inc's market capitalization is USD 6.49B.

What does Cg Oncology Inc do?

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.